NGEN on Nasdaq

NERVGEN PHARMA CORP.

NERVGEN PHARMA CORP. is a Canadian pharmaceutical preparations company based in Vancouver.2 Its shares trade on Nasdaq under the symbol NGEN.2

Price unavailable

Last updated Oct 20, 2026.

Overview

-44.1MNet income, fiscal 20253

Compare with another stock.

  • TickerNGEN on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersVancouver, Canada2
  • Incorporated inBritish Columbia, Canada4
  • Business addressSuite 1703 - 595 Burrard Street, Vancouver, A1 V7X 1J14
  • Filer category, Emerging growth company4
  • Legal formCorporation2
  • LEI549300CZ6Y0WSURPE2032
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address1133 Melville Street, V6E 4E5 Vancouver, Canada2
  • Registered withBC Registry Services, BC11044032

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-1268.9%Return on equity3

Financial statements

Net income3-$44.1M in 2025+82% since 2024
-$60.0M-$40.0M-$20.0M02024: -$24.3M-$24.3M20242025: -$44.1M-$44.1M2025+82%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development (Note 19)13.9M CAD15.8M CAD
General and administrative (Note 19)11.2M CAD9.4M CAD
Total operating expenses25.1M CAD25.2M CAD
Interest income-333.4K CAD-812.6K CAD
Unrealized loss on warrant derivative (Note 15)19.0M CAD136.0K CAD
Foreign exchange loss (gain)409.4K CAD-249.4K CAD
Net loss-44.1M CAD-24.3M CAD
Comprehensive loss-44.1M CAD-24.3M CAD
Basic net loss per share-0.61 CAD-0.36 CAD
Diluted net loss per share-0.61 CAD-0.36 CAD
Weighted average Common Shares outstanding, Basic (in shares)72.3M shares67.3M shares
Weighted average Common Shares outstanding, Diluted (in shares)72.3M shares67.3M shares

Compare NERVGEN PHARMA CORP. with another company

What it owns

What NERVGEN PHARMA CORP. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents22.1M CAD3 Dec 31, 202517.3M CAD3 Dec 31, 2024+27.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)409.2K CAD3 Dec 31, 2025465.0K CAD3 Dec 31, 2024−12.0%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerDaniel Mikol named Dec 14, 20215
  • Director, Executive OfficerPaul Brennan named Dec 14, 20215
  • Executive OfficerWilliam Adams named Dec 14, 20215
  • DirectorBill Radvak named Dec 14, 20215
  • DirectorBrian Bayley named Dec 14, 20215
  • DirectorGlenn Ives named Dec 14, 20215
  • DirectorHarold Punnett named Dec 14, 20215
  • DirectorKrista McKerracher named Dec 14, 20215
  • DirectorMichael Abrams named Dec 14, 20215
  • DirectorRandall Kaye named Dec 14, 20215

Timeline

  1. Jan 19, 2017Founded NERVGEN PHARMA CORP. is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/20266

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

31 filings to the SEC since October 2021: 1 annual reports, 1 private raises, 29 other. The latest 20:

  1. Sep 25, 20266-K EDGAR
  2. Sep 24, 20266-K EDGAR
  3. Aug 13, 20266-K EDGAR
  4. Jul 2, 20266-K EDGAR
  5. Jul 2, 2026SUPPL EDGAR
  6. Jun 1, 20266-K EDGAR
  7. May 26, 2026EFFECT EDGAR
  8. May 26, 20266-K EDGAR
  9. May 26, 2026SUPPL EDGAR
  10. May 26, 2026F-X EDGAR
  11. May 26, 2026F-10 EDGAR
  12. May 22, 20266-K EDGAR
  13. May 22, 2026SUPPL EDGAR
  14. May 21, 2026SUPPL EDGAR
  15. May 18, 20266-K EDGAR
  16. May 15, 20266-K EDGAR
  17. May 7, 2026S-8 EDGAR
  18. Apr 27, 20266-K EDGAR
  19. Mar 31, 202640-F EDGAR
  20. Mar 13, 20266-K EDGAR

The 31 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 29, 2021Raised $651,815 in a private offering of equity Form D: $1.1 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 62. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Empery Asset Management, LP4,000,000$8.2M9.5%New
Rock Springs Capital Management LP1,208,231$2.5M0.1%New
DAFNA Capital Management LLC1,050,000$2.2M0.4%New
Ghisallo Capital Management LLC1,000,000$2.1M0.0%New
Armistice Capital, LLC678,000$1.4M0.0%New
LMR Partners LLP600,000$1.2M0.0%New
Marshall Wace, Llp435,962$898.1K0.0%+235,603
UBS Group AG379,726$782.2K0.0%+318,209
Stonepine Capital Management, LLC271,678$559.7K0.4%New
Jane Street Group, LLC270,750$557.7K0.0%New
Woodline Partners LP250,500$516.0K0.0%New
PFG Investments, LLC217,500$448.1K0.0%+16,500
Bank Of America Corp /de/186,200$383.6K0.0%−14,456
Royal Bank Of Canada176,075$363.0K0.0%+4,114
Bank Of Montreal /can/78,394$284.4K0.0%+15,494
Quadrature Capital Ltd134,518$277.1K0.0%New
Integrated Wealth Concepts LLC74,215$152.9K0.0%−12,600
Captrust Financial Advisors64,423$132.7K0.0%+2,056
Geode Capital Management, LLC58,040$119.6K0.0%New
Osaic Holdings, Inc.51,093$105.2K0.0%+11,102
Axq Capital, LP43,099$88.8K0.0%New
Liberty Wealth Management LLC22,000$82.9K0.0%No change
Millennium Management LLC39,740$81.9K0.0%New
Great Valley Advisor Group, Inc.35,500$73.1K0.0%+14,500
Commonwealth Equity Services, LLC33,000$68.0K0.0%−350

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How NERVGEN PHARMA CORP. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNERVGEN PHARMA CORP.1
  • CIK0001751912
  • Employer ID (EIN)98-17381837
  • Filer status<br>emerging growth company an emerging growth company1
  • Incorporated inBritish Columbia7
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressSuite 1703 - 595 Burrard Street, Vancouver, A1 V7X 1J11
  • Phone60472253611
  • Shares outstanding79,649,257 shares as of Dec 31, 20257
  • AuditorKPMG LLP, Vancouver, Canada PCAOB ID 85; no auditor attestation of internal control over financial reporting7
  • On EDGAR sinceSep 20, 20181
  • Filings39 in all: 6-K (14), D (7), SUPPL (4), D/A (2), EFFECT (2), F-10 (2), F-X (2), S-8 (2)1
    All 12 form types

    40-F (1), 8-A12B (1), CERT (1), F-10/A (1)

  • Latest filingsAnnual report (40-F) Mar 31, 2026

Securities registered for trading

ClassSymbolExchange
Common Shares, no par valueNGENThe Nasdaq Stock Market LLC

From the cover page of the 40-F filed Mar 31, 2026 (Section 12(b) of the Exchange Act).7

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7